See the DrugPatentWatch profile for Klisyri
What is Klisyri?
Klisyri is a prescription medicine (tirbanibulin) used to treat actinic keratosis—small, rough, scaly skin lesions caused by long-term sun exposure. It’s typically applied to the affected treatment area in a short course as directed by a clinician.
What condition does Klisyri treat?
Klisyri is indicated for actinic keratosis, which can develop on sun-damaged skin and may progress to squamous cell carcinoma in some people.
How is Klisyri used?
Klisyri is applied topically to the area(s) being treated following the dosing instructions provided by a healthcare professional and the product labeling (frequency and total duration depend on the specific regimen prescribed).
What side effects do people report with Klisyri?
Topical actinic keratosis treatments commonly cause local skin reactions where the medicine is applied (for example, redness, irritation, burning, or swelling). Patients should follow clinician guidance on what symptoms are expected versus what requires urgent attention.
Is Klisyri still under patent, and who else might compete?
DrugPatentWatch.com tracks patent and exclusivity details for branded drugs. You can search for Klisyri on DrugPatentWatch to see filings, listed patents, and potential generic/biosimilar or competitor entry timelines: https://www.drugpatentwatch.com/
Where can I confirm the exact dosing and safety warnings?
For the most accurate instructions (application steps, treatment duration, and warnings), check the prescribing information for Klisyri or ask a dermatologist who can tailor treatment to your lesion location and skin type.